Cost-effectiveness of extended cessation treatment for older smokers
- PMID: 24329972
- PMCID: PMC4020783
- DOI: 10.1111/add.12404
Cost-effectiveness of extended cessation treatment for older smokers
Abstract
Aims: We examined the cost-effectiveness of extended smoking cessation treatment in older smokers.
Design: Participants who completed a 12-week smoking cessation program were factorial randomized to extended cognitive behavioral treatment and extended nicotine replacement therapy.
Setting: A free-standing smoking cessation clinic.
Participants: A total of 402 smokers aged 50 years and older were recruited from the community.
Measurements: The trial measured biochemically verified abstinence from cigarettes after 2 years and the quantity of smoking cessation services utilized. Trial findings were combined with literature on changes in smoking status and the age- and gender-adjusted effect of smoking on health-care cost, mortality and quality of life over the long term in a Markov model of cost-effectiveness over a lifetime horizon.
Findings: The addition of extended cognitive behavioral therapy added $83 in smoking cessation services cost [P = 0.012, confidence interval (CI) = $22-212]. At the end of follow-up, cigarette abstinence rates were 50.0% with extended cognitive behavioral therapy and 37.2% without this therapy (P < 0.05, odds ratio 1.69, CI 1.18-2.54). The model-based incremental cost-effectiveness ratio was $6324 per quality-adjusted life year (QALY). Probabilistic sensitivity analysis found that the additional $947 in lifetime cost of the intervention had a 95% confidence interval of -$331 to 2081; the 0.15 additional QALYs had a confidence interval of 0.035-0.280, and that the intervention was cost-effective against a $50 000/QALY acceptance criterion in 99.6% of the replicates. Extended nicotine replacement therapy was not cost-effective.
Conclusions: Adding extended cognitive behavior therapy to standard cessation treatment was cost-effective. Further intensification of treatment may be warranted.
Trial registration: ClinicalTrials.gov NCT00086385.
Keywords: Clinical trial; Markov model; cognitive behaviorial treatment; cost-effectiveness analysis; extended smoking cessation; incremental cost-effectiveness ratio; tobacco use cessation.
© 2013 Society for the Study of Addiction.
References
-
- Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. Jama. 1989;261:75–9. - PubMed
-
- Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. Jama. 1997;278:1759–66. - PubMed
-
- Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling. Jama. 1996;275:1247–51. - PubMed
-
- Song F, Raftery J, Aveyard P, et al. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002;22:S26–37. - PubMed
-
- Coleman T, Agboola S, Leonardi-Bee J, et al. Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis. Health Technol Assess. 2010;14:1–152. iii–iv. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
